✦ LIBER ✦

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure

✍ Scribed by Massarweh, Suleiman; Romond, Edward; Black, Esther P.; Meter, Emily; Shelton, Brent; Kadamyan-Melkumian, Vera; Stevens, Mark; Elledge, Richard

Book ID: 121579452
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 275 KB
Volume: 143
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2810-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of sorafenib with anast

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

✍ Claudine Isaacs; Pia Herbolsheimer; Minetta C. Liu; Mary Wilkinson; Yvonne Ottav 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 220 KB

A phase II neoadjuvant trial of anastroz

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

✍ Suleiman Massarweh; Yee L. Tham; Jian Huang; Krystal Sexton; Heidi Weiss; Anna T 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 361 KB

Fulvestrant plus anastrozole or placebo

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

✍ Johnston, Stephen RD; Kilburn, Lucy S; Ellis, Paul; Dodwell, David; Cameron, Dav 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 459 KB

A phase II trial of letrozole in combina

A phase II trial of letrozole in combination with bevacizumab in patients with hormone receptor-positive metastatic breast cancer: Correlation of response with circulating endothelial (CEC) and epithelial cells (CTC)

✍ H. Rugo; Dickler; Y. Traina; J. Scott; D. Moore; E. Brogi; J. Bruckner; S. Flore 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 271 KB

A multicentre dose-escalating study of c

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

✍ C. Villanueva; A. Awada; M. Campone; J.P. Machiels; T. Besse; E. Magherini; F. D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB